  Novel diagnostic and therapeutic radiopharmaceuticals are increasingly
becoming a central part of personalized medicine. Continued innovation in the
development of new radiopharmaceuticals is key to sustained growth and
advancement of precision medicine. Artificial intelligence (AI) has been used
in multiple fields of medicine to develop and validate better tools for patient
diagnosis and therapy, including in radiopharmaceutical design. In this review,
we first discuss common in silico approaches and focus on their utility and
challenges in radiopharmaceutical development. Next, we discuss the practical
applications of in silico modeling in design of radiopharmaceuticals in various
diseases.
